Trial · NCT01321827
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
NCT01321827, Phase 2, Phase 3, Completed, Post Graduate Institute of Medical Education and Research, Chandigarh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis. Trials, record NCT01321827. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01321827
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
- NCT number
- NCT01321827
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 100 participants, actual
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- Interventions
- Glucocorticoids, Itraconazole
- First posted
- 2011-03-24
- Last updated
- 2017-03-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Remission rates in the two groups at six weeks and three months | 6 weeks, 3 months | Remission - if the IgE levels decline by \>=25% and there is clinical improvement with partial/total clearance of chest radiographic lesions after three months of glucocorticoids (if previously present pulmonary opacities) |
| Primary | Percentage decline in IgE levels at six weeks and three months | 6 weeks, 3 months | IgE levels will be noted at baseline six weeks and three months after glucocorticoid therapy and percentage decline will be calculated as: (baseline IgE levels minus IgE levels after six weeks of treatment) divided by baseline IgE levels |
| Primary | Complete remission rates in the two groups | 3 months, 6 months | No ABPA exacerbations over the next 3 months after stopping therapy |
| Secondary | Relapse rates in the two groups at six and 12 months after completion of treatment | 6 months, 12 months | Relapse - doubling of the baseline IgE levels irrespective of the patient's symptoms or appearance of radiologic infiltrates |
| Secondary | Treatment related adverse effects in the two groups | Every 6 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29331473 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01321827
GET https://conductscience.org/api/trials/v1/NCT01321827/registered